Get started

Cypher

GBP/CHF - Anticipating Bearish Momentum from Key ResistanceGBP/CHF is forming an Anti-Cypher Harmonic Pattern (XABCD) on the 4-hour chart. This pattern indicates a potential reversal in the current trend. Key Levels and Trendlines: The price is approaching a key resistance area and a 4-hour trendline, suggesting a possible reversal from the bullish momentum. Entry and Stop Loss: Considering the Anti-Cypher pattern and the resistance levels, a prudent entry point for a short position is 1.1385. The stop loss should be placed at 1.14500 to mitigate potential losses. Take Profit Targets: We have identified three take-profit targets TP-1: 1.13235 TP-2: 1.12650 TP-3: 1.12035 These levels align with potential support areas and provide suitable profit-taking opportunities. Conclusion: Based on the analysis of the Anti-Cypher pattern, key resistance levels, and trendlines, we anticipate a bearish momentum from Point D. Traders may consider entering short positions at 1.1385 with stop loss at 1.14500 and targeting TP levels at 1.13235, 1.12650, and 1.12035 respectively. As always, it's essential to closely monitor the market for any changes and adjust the strategy accordingly.
Short
by trading_jupiter
11
GBP/CAD Harmonic Pattern Signals Bearish OpportunityOverview: GBP/CAD has recently exhibited the formation of an Anti-Butterfly XABCD harmonic pattern, concomitant with the price approaching a crucial Resistance area. This confluence suggests a potential Bearish reversal from point D, indicating a favorable opportunity for traders to capitalize on the impending downward movement. Entry Strategy: A prudent entry point for this trade is near 1.72840. This level aligns with the anticipated reversal point, providing an optimal entry opportunity for traders seeking to capitalize on the projected Bearish momentum. Stop Loss Placement: To mitigate potential risks associated with adverse price movements, it is advisable to place a Stop Loss order near 1.72480. This strategically positioned Stop Loss serves to safeguard against unexpected market fluctuations while allowing for ample room for the trade to unfold in alignment with the projected analysis. Take Profit Targets: 1. TP-1: 1.71175 2. TP-2: 1.70525 3. TP-3: 1.69869 Conclusion: In conclusion, the technical analysis of GBP/CAD suggests a compelling Bearish trading opportunity, characterized by the formation of an Anti-Butterfly XABCD harmonic pattern and proximity to key Resistance levels. By adhering to the outlined entry, stop loss, and take profit strategies, traders can effectively navigate the market dynamics and capitalize on the anticipated Bearish movement with confidence and precision.
Short
by trading_jupiter
4
SAND/USDT Technical Analysis - Potential Bullish OpportunitySAND/USDT has exhibited a notable XABCD harmonic pattern formation, coinciding with a pivotal support level. This suggests a potential bullish reversal from point D, indicating favorable trading opportunities for discerning investors. Harmonic Pattern Analysis: The XABCD harmonic pattern observed in SAND/USDT signals a systematic price structure characterized by precise Fibonacci relationships. The completion of this pattern at point D suggests a high probability of trend reversal, presenting an optimal entry point for bullish positions. Key Support Area: The convergence of the XABCD pattern with a key support area strengthens the bullish bias, reinforcing the significance of the anticipated price movement. This confluence enhances the reliability of our analysis and underscores the importance of the identified entry level. Entry Strategy: We recommend initiating long positions near the price level of 0.5053, strategically aligning with the completion of the harmonic pattern and the established support region. This entry point offers favorable risk-reward dynamics and positions traders advantageously for potential upside movements. Risk Management: To mitigate downside risks, it is prudent to implement a stop-loss order near 0.3532. This predefined exit point safeguards capital and preserves trading discipline, ensuring minimal losses in the event of adverse price fluctuations. Profit Targets: Our profit-taking strategy encompasses two distinct targets to capitalize on the anticipated bullish momentum. The initial profit target (TP-1) is set at 0.6584, representing a conservative approach to securing gains. Subsequently, the secondary profit target (TP-2) is identified at 0.8115, offering the potential for extended profitability as the uptrend unfolds. Conclusion: In conclusion, the technical analysis of SAND/USDT reveals a compelling bullish outlook, characterized by the formation of a XABCD harmonic pattern and the confluence with a key support area. By adhering to the suggested entry, stop-loss, and profit-taking levels, traders can optimize their trading strategy and capitalize on the anticipated price appreciation. Disclaimer: This analysis is based solely on technical indicators and historical price data. It is imperative to conduct thorough risk assessments and exercise prudent risk management practices when executing trades in the financial markets.*
BINANCE:SANDUSDLong
by trading_jupiter
OCFC (D) Cypher HarmonicThe information contained herein has been prepared for general information purposes only. The comments and recommendations contained herein are based on the personal opinions of commenters and advice givers. It should not be interpreted as a recommendation to buy or sell any investment instrument or a promise of return. These views may not be suitable for your financial situation and risk and return preferences. Therefore, making an investment decision based solely on the information contained herein may not produce results that meet your expectations.
NASDAQ:OCFCLong
by AliHikmetHarun
Bitcoin Cup and Handle?Owhooooo! This weekly chart has me howling for the moon! It seems like the Bullish Cypher is still playing out, and the giant Cup and Handle formation could be in play. If we do see a pullback, I think this would fit nicely into the overall continuation of the Bullish Cypher trend. So I'll be looking for this pullback to form the handle, and my own personal strategy is to use this (if it happens) to accumulate MORE Bitcoin. I'll be hiding in the bushes and waiting to see how this plays out. What do you think will happen?
BINANCE:BTCUSD
by Akamer-the-Werewolf
Raising EURUSD Profit Target to $1.114 due to a Bullish CypherDue to the apparent formation of a Bullish Cypher on the Daily, combined with the Bullish Push as confirmation on the RSI, and the strong push push in price action above the 200-day SMA, I will be raising my profit target for the EURUSD to the 100% retrace up at $1.114 as the 100% retrace would be the standard target for a Cypher and the TLT has outperformed which is usually a signal for psoitive price action in the EURUSD.
Long
by RizeSenpai
DOGE can crash by a 64%. Here is whyDoge can crash by a 64%. Why? Because we have a descending triangle on the weekly chart, which is a bearish pattern. Also, how much % profit DOGE made in 2023? 0%. DOGE is going sideways. Do not get me wrong, I believe in future on DOGE, but investors are disappointed compared to other coins. I think we can buy cheap doge in 2024 / 2025. Then to the moon. Let me know what you think about my analysis, and please hit boost and follow for more ideas. Thank you, and I wish you successful trades! Dogecoin differs from Bitcoin's proof-of-work protocol in several ways, one of which is by using Scrypt technology. The altcoin has also a block time of 1 minute, and the total supply is uncapped, which means that there is no limit to the number of Dogecoin that can be mined. You can mine Dogecoin either solo, or by joining a mining pool. A Doge miner can mine the digital currency on Windows, Mac or Linux, and with a GPU. As of 2014, you can also mine Litecoin in the same process of mining Dogecoin, as the processes were merged. Let me know what you think about my analysis, and please hit boost and follow for more ideas. Thank you, and I wish you successful trades!
Short
by Xanrox
15
$OCUL Ocular Therapeutix Inc Long term Target PT 29 and higherNASDAQ:OCUL Ocular Therapeutix Inc Long term Target PT 29 and higher Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
NASDAQ:OCULLong
by BADQOMOCAWGOWLD
$ETNB 89bio Inc Target PTs 29 --> 20 --> 43 and higherNASDAQ:ETNB 89bio Inc Target PTs 29 --> 20 --> 43 and higher 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
NASDAQ:ETNBLong
by BADQOMOCAWGOWLD